BCMA-targeted BiTEs for multiple myeloma скачать в хорошем качестве

BCMA-targeted BiTEs for multiple myeloma

Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, gives an overview of the use of B-cell maturation antigen (BCMA)-targeted T-cell redirectors, and discusses how these fit into the treatment landscape for myeloma. Prof. van de Donk talks on the anti–BCMA bispecific T-cell engager (BiTE) pacanlotamab, previously known as AMG 420, which first demonstrated the efficacy of BCMA-targeted T-cell redirectors, producing response rates of 70-80% in heavily pretreated populations. Prof. van de Donk also talks on the latest clinical data from immunoglobulin G (IgG)-like bispecific antibodies such as elranatamab and explains the toxicity profiles for each. Prof. van de Donk further comments on novel combinations with anti-CD38 antibodies and immunomodulatory imide drugs (IMiDs), as well as with other antibodies such as teclistamab and talquetamab. Finally, Prof. van de Donk discusses the role of chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of myeloma, highlighting pros and cons in comparison to BiTEs. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.